NLS Agreement

The companies have entered into a supply and commercialization agreement for AVT10, Alvotech’s biosimilar candidate to Cimzia (certolizumab pegol).

The two companies will advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD), including alpha-mannosidosis (aMann) and Krabbe disease (KD), ultra-rare diseases that affect the central nervous system.

Camurus and Eli Lilly and Company (Lilly) have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health based on Camurus’ FluidCrystal technology.

Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited, have entered into an agreement to commercialize Recombinant Human Albumin in Europe.

The collaboration will complement PeptiSystems’ flow-based instrumentation systems with Asahi Kasei Bioprocess America (AKBA)’s column technology.

This collaboration represents a powerful alignment of capabilities designed to address the growing complexity of global regulatory requirements, the companies state.